Peter Greenleaf - Sucampo Pharmaceuticals Chairman and CEO
Chairman
Mr. Peter Greenleaf was appointed as the Chairman of the Board, Chief Executive Officer of the Company. He was Director of the Sucampo Pharmaceuticals Inc. Prior to his leadership of Sucampo, Mr. Greenleaf was CEO and Board member of Histogenics Corporationrationration, a regenerative medicine company, from June 2013 through February 2014. From 2008 to June 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. While at MedImmune, Mr. Greenleaf was instrumental in driving the expansion of MedImmunes pipeline into over 120 clinical and preclinical programs and the commercialization of its marketed products. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. from 1998 to 2006 and prior to that Boehringer Mannheim G.m.b.H. from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a publicprivate partnership to spur VC investment in the state since 2016.
| Age | 46 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 301 961-3400 |
| Web | www.sucampo.com |
Peter Greenleaf Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Greenleaf against Sucampo Pharmaceuticals stock is an integral part of due diligence when investing in Sucampo Pharmaceuticals. Peter Greenleaf insider activity provides valuable insight into whether Sucampo Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Sucampo Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sucampo Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Greenleaf over two months ago Acquisition by Peter Greenleaf of 661538 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 |
Sucampo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Michael Freno | Barings BDC | 43 | |
| Lazaro Brandao | Barings BDC | 88 | |
| Andrew Ziegler | Artisan Partners Asset | 62 | |
| Eric Colson | Artisan Partners Asset | 51 | |
| Eric Lloyd | Barings BDC | 54 | |
| Wichian Phongsathorn | Pintec Technology Holdings | 58 | |
| Antonio Bornia | Barings BDC | 78 | |
Management Performance
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 |
Sucampo Pharmaceuticals Leadership Team
Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Munder, Independent Director | ||
| Peter Pfreundschuh, CFO, Principal Financial Officer | ||
| Matthew Donley, Executive VP of HR | ||
| Max Donley, Executive Vice President of Human Resources | ||
| Peter Kiener, Chief Scientific Officer | ||
| Matthias Alder, Executive Vice President - Business Development & Licensing | ||
| Daniel Getman, Independent Chairman of the Board | ||
| Peter Greenleaf, Chairman and CEO | ||
| Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications | ||
| Peter Lichtlen, Chief Medical Officer | ||
| Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC | ||
| Andrew Smith, Principal Accounting Officer | ||
| Timothy Walbert, Director | ||
| John Johnson, Director | ||
| Paul Edick, Director | ||
| Alex Driggs, Acting General Counsel, Corporate Secretary | ||
| Karen Smith, Director | ||
| Robert Spiegel, Director | ||
| Maureen OConnell, Independent Director | ||
| Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary |
Sucampo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 | |||
| Profit Margin | 7.80 % | |||
| Operating Margin | 30.77 % | |||
| Current Valuation | 1.05 B | |||
| Shares Outstanding | 47.09 M | |||
| Shares Owned By Insiders | 35.13 % | |||
| Shares Owned By Institutions | 82.48 % | |||
| Number Of Shares Shorted | 4.59 M | |||
| Price To Earning | (2.77) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sucampo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sucampo Pharmaceuticals' short interest history, or implied volatility extrapolated from Sucampo Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Sucampo Stock
If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |